Is a pIND meeting always a prerequisite for success, or is it sometimes a bottleneck?

Many in our industry view the pre-IND meeting as a mandatory rite of passage, a non-negotiable step in every drug development journey. But I challenge that assumption. While invaluable in certain complex scenarios, blanket application can inadvertently slow down groundbreaking innovation.

My experience suggests that the true value of a pIND lies in mitig…